Lupin
Ticker > Company >

Lupin share price

Lupin Ltd.

NSE: LUPIN BSE: 500257 SECTOR: Pharmaceuticals & Drugs  263k   816   134

2150.70
-12.15 (-0.56%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 2177.75

Today's Low

₹ 2138.4

52 Week High

₹ 2312

52 Week Low

₹ 1266.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 98114.41 Cr.

Enterprise Value

₹ 97993.9 Cr.

No. of Shares

45.62 Cr.

P/E

32.73

P/B

4.46

Face Value

₹ 2

Div. Yield

0.37 %

Book Value (TTM)

₹  481.77

CASH

₹ 138.64 Cr.

DEBT

₹ 18.13 Cr.

Promoter Holding

46.96 %

EPS (TTM)

₹  65.71

Sales Growth

30.27%

ROE

12 %

ROCE

14.33%

Profit Growth

447.05 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Lupin Ltd.

Molnulup Respira endeavour maxter pinnacle blue eyes femina midvision CVN

Index Presence

The company is present in 41 Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
64986.65
  -1961.65 (-2.93009680604287%)

NIFTYMIDCAP

NIFTY Midcap 100
56906.75
  -1649.5 (-2.81694951435586%)

NIFTYALPHA

Nifty Alpha 50
56427.75
  -1661.65 (-2.86050467038738%)

NFTY200MOM30

Nifty200 Momentum 30
33126.55
  -1039.14999999999 (-3.04150068636087%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
27263.45
  -431.649999999998 (-1.55857895439987%)

NT200ALP30

NIFTY200 Alpha 30
26087.8
  -710.700000000001 (-2.65201410526709%)

NIFTYLOWVOL

Nifty Low Volatility 50
23608.15
  -323.349999999999 (-1.35114806844535%)

NIFTYPHARMA

Nifty Pharma
22501.85
  -196.050000000003 (-0.863736292784811%)

NIFTY500

Nifty 500
22319.4
  -432.75 (-1.90201805104133%)

NIFTYMIDCAP150

Nifty Midcap 150
21050.6
  -520.700000000001 (-2.41385544682055%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19899.4
  -461.949999999997 (-2.26875919327548%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17537.05
  -369.299999999999 (-2.06239685921474%)

MIDCAP50

Nifty Midcap 50
15881.1
  -441.65 (-2.70573279625063%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15748.9
  -319.200000000001 (-1.98654476882768%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15666
  -334.75 (-2.09208943330781%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14551.55
  -267.35 (-1.80411501528454%)

NIFTYHEALTH

Nifty Healthcare Index
14474.9
  -119.950000000001 (-0.821865246987807%)

LIX 15 MIDCAP

Nifty Midcap Liquid 15
14261.5
  -408.950000000001 (-2.78757638654575%)

NFT500EQUAL

Nifty 500 Equal Weight
14164.9
  -298.9 (-2.06653853067659%)

NIFTYMFG

NIFTY India Manufacturing
13771.1
  -299 (-2.12507373792653%)

NIFTY200

Nifty 200
13373.9
  -264.25 (-1.93757951041746%)

NIFTYMIDSELECT

Nifty Midcap Select
12683.15
  -344.050000000001 (-2.64101265045444%)

NIFTYTOTALMCAP

NIFTY Total Market
12606.65
  -246.4 (-1.91705470685946%)

SNXT50

Bse Sensex Next 50
81296.27
  -2178.76999999999 (-2.61008560163611%)

MIDCAP

Bse MidCap
46226.5
  -1152.75 (-2.43302711630091%)

BSE HC

Bse Healthcare
44095.46
  -505.020000000004 (-1.13231965216519%)

BSE500

Bse 500
35082.25
  -680.419999999998 (-1.90259843574319%)

BSE100

Bse 100
25006.81
  -448.199999999997 (-1.76075358053286%)

FOCMID

BSE Focused Midcap
24293.76
  -607.960000000003 (-2.44143778020154%)

MIDSEL

Bse MidCap Select Index
17422.11
  -494.739999999998 (-2.76131127960551%)

MID150

Bse 150 MidCap Index
15862.89
  -381.58 (-2.34898399270644%)

200EQW

BSE 200 Equal Weight
12603.9
  -281.110000000001 (-2.18168243563646%)

MSL400

Bse 400 MidSmallCap Index
12101.72
  -276.790000000001 (-2.23605264284636%)

BSE200

Bse 200
10905.86
  -210.17 (-1.89069299021324%)

LMI250

Bse 250 LargeMidCap Index
10353.28
  -199.23 (-1.88798683915011%)

SPBSMOIP

BSE Momentum Index
2210.33
  -73.25 (-3.20768267369657%)

ESG100

Bse 100 ESG Index
392.41
  -6.13 (-1.53811411652531%)

ALLCAP

Bse Allcap
10471.31
  71.0699999999997 (0.683349615008888%)

S&P LARGEMIDCAP

Bse LargeMidCap
10238.39
  -197.890000000001 (-1.89617373240275%)

S&P MIDSMLCAP

Bse MidSmallCap
13527.25
  -313.42 (-2.26448575105107%)

CARBONEX

Bse Carbonex
4344.48
  15.7799999999997 (0.364543627417002%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year30.27%
3 Year9.88%
5 Year5.25%

Profit Growth

1 Year447.04%
3 Year22.72%
5 Year8.61%

ROE%

1 Year12%
3 Year4.44%
5 Year4.93%

ROCE %

1 Year14.33%
3 Year5.72%
5 Year6.55%

Debt/Equity

0.0009

Price to Cash Flow

39.18

Interest Cover Ratio

50.4177

CFO/PAT (5 Yr. Avg.)

1.81119731268013

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 46.96 0.00
Jun 2024 46.98 0.00
Mar 2024 47.01 0.00
Dec 2023 47.04 0.00
Sep 2023 47.06 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 22.7186668112775% for the Past 3 years.
  • The company has significantly decreased its debt by 595.33 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 50.4177.
  • Company’s PEG ratio is 0.0733579259446457.
  • The company has an efficient Cash Conversion Cycle of -1.21610000000001 days.
  • Company has a healthy liquidity position with current ratio of 2.5066.
  • The company has a good cash flow management; CFO/PAT stands at 1.81119731268013.

 Limitations

  • The company has shown a poor revenue growth of 9.87780953620883% for the Past 3 years.
  • Company has a poor ROE of 4.43752488278403% over the past 3 years.
  • Company has contingent liabilities of 4029.78 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 3659.23 4115.75 3395.88 4167.63 4106.2
Total Expenditure 2823.99 2898.41 2695.53 2968.82 2991.45
Operating Profit 835.24 1217.34 700.35 1198.81 1114.75
Other Income 25.6 23.16 31.34 39.08 32.62
Interest 15.32 11.36 13.49 13.55 17.55
Depreciation 149.48 145.18 290.04 141.42 145.77
Exceptional Items 0 0 0 0 0
Profit Before Tax 696.04 1083.96 428.16 1082.92 984.05
Tax 147.43 167.52 44.08 193.74 176.29
Profit After Tax 548.61 916.44 384.08 889.18 807.76
Adjusted EPS (Rs) 12.05 20.13 8.43 19.5 17.71

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 11025.66 11055.93 11771.67 11258.83 14666.5
Total Expenditure 9118.05 9011.87 11566.69 10294.93 11227.12
Operating Profit 1907.61 2044.06 204.98 963.9 3439.38
Other Income 475.19 129.09 221.15 210.02 126.41
Interest 52.59 40.62 73.47 98.44 56.35
Depreciation 518.75 502.83 514.19 548.34 724.75
Exceptional Items -759.21 0 0 0 0
Profit Before Tax 1052.25 1629.7 -161.53 527.14 2784.69
Tax 324.7 371.08 27.17 101.93 458.6
Net Profit 727.55 1258.62 -188.7 425.21 2326.09
Adjusted EPS (Rs.) 16.06 27.74 -4.15 9.35 51.04

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 90.6 90.74 90.9 91 91.14
Total Reserves 17382.6 18474.83 18059.29 18320.86 20511.95
Borrowings 0.31 0.15 0 0 0
Other N/C liabilities 651.2 707.01 625.27 643.96 625.83
Current liabilities 2555.79 2585.83 3537.91 3627.85 3646.42
Total Liabilities 20680.5 21858.56 22313.37 22683.67 24922.86
Assets
Net Block 3513.88 3638.83 3690.18 4021.93 4113.17
Capital WIP 694.63 795.83 773.74 737.99 411.12
Intangible WIP 127.37 155.03 173.7 188.6 34.71
Investments 5126.7 7241.59 8688.69 9534.56 10771.82
Loans & Advances 376.38 399.62 537.04 603.86 231.19
Other N/C Assets 3.03 10.29 12.2 25.81 220.67
Current Assets 10838.51 9617.37 8437.82 7570.92 9140.18
Total Assets 20680.5 21858.56 22313.37 22683.67 24922.86
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1052.25 1629.7 -161.53 527.14 2784.69
Adjustment 718.54 487.06 449.36 583.79 771.3
Changes in Assets & Liabilities 834.62 -118.04 -284.97 809.86 -905.21
Tax Paid -385.92 -428.64 148.17 -126.8 -146.65
Operating Cash Flow 2219.49 1570.08 151.03 1793.99 2504.13
Investing Cash Flow -739.56 -2507.52 -371.79 -1269.17 -1599.02
Financing Cash Flow -367.85 -53.17 102.45 -498.26 -867.07
Net Cash Flow 1112.08 -990.61 -118.31 26.56 38.04

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 47.06 47.04 47.01 46.98 46.96
anuja gupta 0.16 0.16 0.16 0.16 0.16
desh bandhu gupta huf 0.14 0.14 0.14 0.14 0.14
kavita gupta 0.04 0.04 0.04 0.04 0.04
lupin investments pvt ltd... 45.52 45.50 45.47 45.45 45.42
manju d gupta 0.85 0.85 0.85 0.85 0.85
neel deshbandhu gupta 0.01 0.01 0.01 0.01 0.01
nilesh d gupta 0.20 0.20 0.20 0.20 0.20
richa gupta 0.05 0.05 0.05 0.05 0.05
veda nilesh gupta 0.02 0.02 0.02 0.02 0.02
vinita gupta 0.07 0.07 0.07 0.07 0.07
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 52.94 52.96 52.99 53.02 53.04
axis mutual fund trustee ... - - - - 1.30
hdfc life insurance compa... 1.68 1.48 1.37 1.33 1.38
hdfc trustee company ltd-... 3.68 3.84 3.11 3.60 3.37
icici prudential value di... - - 4.31 3.46 2.54
investor education and pr... 0.17 - - - 0.16
life insurance corporatio... 8.23 6.14 5.87 5.13 2.89
llp - - - 0.12 0.05
mirae asset large and mid... - 1.76 1.49 1.53 1.02
nippon life india trustee... 1.77 1.89 1.87 1.86 1.81
sbi life insurance compan... - - - - 1.04
sbi long term equity fund... 1.09 1.23 1.14 1.17 1.60
investor education and pr... - 0.17 0.17 0.17 -
government pension fund g... 1.38 1.12 - - -
icici prudential bluechip... 5.14 5.25 - - -
mirae asset emerging blue... 1.68 - - - -
nps trust - a/c hdfc pens... 1.02 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Lupin gets USFDA’s nod for Emtricitabine and Tenofovir Alafenamide Tablets 19 Dec, 11:29 AM Lupin informs about disclosures 9 Dec, 5:03 PM Lupin’s arm recalling over 6 lakh bottles of Ramipril capsules in US 26 Nov, 2:40 PM Lupin reports 74% rise in Q2 consolidated net profit 8 Nov, 2:28 PM Lupin - Quaterly Results 7 Nov, 6:34 PM Lupin - Quaterly Results 7 Nov, 6:34 PM Lupin - Quaterly Results 7 Nov, 6:34 PM Lupin informs about allotment of shares under ESOP 23 Oct, 4:11 PM Lupin launches first generic version of Pred Forte in United States 15 Oct, 2:26 PM Lupin informs about press release 15 Oct, 12:12 PM Lupin informs about details of loss of certificate 9 Oct, 4:59 PM USFDA completes pre-approval inspection at Lupin’s Biotech facility in Pune 7 Oct, 9:29 AM Lupin informs about disclosure 5 Oct, 3:13 PM Lupin informs about loss of share certificate 1 Oct, 4:32 PM Lupin inks distribution pact with Scope Ophthalmics 1 Oct, 11:42 AM USFDA inspects Lupin’s manufacturing facility at Pithampur Unit-1 28 Sep, 4:02 PM Lupin informs about US FDA inspection 28 Sep, 11:47 AM Lupin informs about loss of share certificate 23 Sep, 5:21 PM Lupin enters into non-exclusive patent license agreement with Takeda 18 Sep, 2:59 PM Lupin to make equity investment in Sunsure Solarpark 11 Sep, 5:18 PM Lupin’s arm recalling 4,554 bottles of Cefixime for Oral Suspension in US market 5 Sep, 12:12 PM Lupin launches Mirabegron Extended-Release Tablets in United States 4 Sep, 3:00 PM Lupin informs about loss of share certificate 28 Aug, 5:28 PM Lupin informs about details of loss of certificate 21 Aug, 5:00 PM Lupin informs about loss of share certificate 20 Aug, 12:34 PM Lupin’s arm incorporates wholly owned subsidiary in New Zealand 8 Aug, 2:59 PM Lupin reports strong Q1 numbers; consolidated net profit jumps 78% 7 Aug, 10:41 AM Lupin - Quaterly Results 6 Aug, 9:03 PM Lupin - Quaterly Results 6 Aug, 9:03 PM Lupin incorporates wholly owned subsidiary in Sri Lanka 6 Aug, 11:37 AM Lupin informs about loss of share certificate 1 Aug, 3:34 PM Lupin informs about allotment of ESOP 26 Jul, 4:21 PM Lupin informs about board meeting 23 Jul, 2:36 PM Lupin divests U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences 15 Jul, 4:46 PM Lupin gets EIR from USFDA for Dabhasa manufacturing facility 12 Jul, 4:29 PM Lupin informs about loss of share certificate 24 Jun, 2:08 PM Lupin gets EIR from USFDA for Somerset manufacturing facility 22 Jun, 4:45 PM Lupin informs about committee meeting 21 Jun, 12:24 PM Lupin informs about press release 17 Jun, 1:31 PM Lupin informs about change in management 17 Jun, 12:11 PM USFDA completes inspection at Lupin’s injectable facility in Nagpur 14 Jun, 11:36 AM Lupin informs about press release 14 Jun, 11:08 AM Lupin’s arm recalls 51,006 bottles of Cefdinir for Oral Suspension 10 Jun, 2:23 PM Lupin enters into BTA with Lupin Life Sciences 10 Jun, 10:30 AM Lupin informs about press release 5 Jun, 5:33 PM Lupin’s arm completes acquisition of two brands from Sanofi in Europe, Canada 5 Jun, 12:10 PM Lupin informs about details of loss of certificate 4 Jun, 1:06 PM USFDA concludes pre approval inspection at Lupin’s Somerset manufacturing facility 20 May, 11:01 AM Lupin informs about press release 9 May, 2:21 PM Lupin informs about investor presentation 7 May, 2:53 PM

Lupin Stock Price Analysis and Quick Research Report. Is Lupin an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Lupin and its performance over the period of time. Lupin stock price today is Rs 2150.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Lupin cash from the operating activity was Rs 2504.13 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Lupin has a Debt to Equity ratio of 0.0009 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Lupin , the EPS growth was 446.2029 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Lupin has OPM of 23.4505846657348 % which is a good sign for profitability.
     
  • ROE: Lupin have a average ROE of 12.0045 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Lupin is Rs 2150.7. One can use valuation calculators of ticker to know if Lupin share price is undervalued or overvalued.
Last Updated on:
Brief about Lupin

Lupin Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Welcome to our Lupin Ltd. stock analysis page, where long-term investors can find a wealth of information and resources to make informed decisions about their investment positions. We provide a comprehensive analysis of various aspects of Lupin Ltd.'s stock performance, allowing investors to gain valuable insights into the company's financial stability, growth prospects, and long-term viability. Let us delve into each topic in detail.

Lupin Ltd. Share Price Analysis

Analyzing the share price of Lupin Ltd. is crucial for long-term investors to understand the company's growth potential and market sentiment. Our pre-built screening tools enable investors to track the historical share price of Lupin Ltd. over different timeframes. By studying price trends, trading volumes, trading range, and the stock's relative performance compared to market indices, investors gain insights into Lupin Ltd.'s financial stability, growth prospects, and investment viability. In addition to these screening tools, our platform provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which offer a more comprehensive analysis of Lupin Ltd.'s intrinsic value and growth potential.

Lupin Ltd. Balance Sheet Evaluation

Evaluating Lupin Ltd.'s balance sheet is a critical step for long-term investors to understand the company's financial position and growth potential. Our pre-built screening tools enable investors to determine Lupin Ltd.'s balance sheet ratios and metrics. By examining key financial indicators such as current assets, current liabilities, and long-term debt, investors gain insights into Lupin Ltd.'s financial stability, liquidity, and potential for growth. Additionally, our platform provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which provide a more comprehensive analysis of Lupin Ltd.'s balance sheet, helping investors assess its long-term investment potential.

Lupin Ltd. Annual Report Insights

Lupin Ltd.'s annual reports offer a wealth of information about the company's performance, strategies, and plans. On our platform, you can access downloadable PDF versions of Lupin Ltd.'s annual reports, along with expert reviews and analysis. These annual reports provide insights into Lupin Ltd.'s business model, competitive landscape, and macroeconomic factors that may impact its operations. Coupled with our premium features tools, investors can conduct a thorough analysis and make well-informed decisions based on Lupin Ltd.'s annual reports.

Lupin Ltd. Dividend Payments

Analysing Lupin Ltd.'s dividend payments is crucial for long-term investors seeking stable returns. Our stock analysis page provides comprehensive data on the company's dividend payment history. By analysing Lupin Ltd.'s profitability, dividend policy, and metrics such as the dividend yield and payout ratio, investors can make well-informed decisions about their long-term investment positions. Alongside our dividend payment information, our platform offers premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which allow investors to evaluate the impact of dividends on Lupin Ltd.'s stock value and overall investment strategy.

Lupin Ltd. Quarterly Results Analysis

Analyzing Lupin Ltd.'s quarterly results helps investors evaluate its short-term performance and gauge its future growth potential. On our platform, you can find downloadable PDF files of Lupin Ltd.'s quarterly results, enabling investors to assess the company's recent performance and key financial metrics such as revenue growth, earnings per share, and margins. By leveraging our premium features tools and conducting a thorough analysis, long-term investors can make well-informed decisions regarding their investment positions in Lupin Ltd.

Lupin Ltd. Stock Price Trends

Analyzing Lupin Ltd.'s stock price trends is essential for understanding its growth potential and market sentiment. Our pre-built screening tools enable investors to track Lupin Ltd.'s stock price trends over different timeframes. This allows the identification of short-term and long-term patterns and pricing volatility. By utilizing our premium features tools, investors gain additional insights into factors affecting Lupin Ltd.'s stock performance, aiding them in making well-informed decisions.

Lupin Ltd. Price Charts

Technical analysis through price chart analysis provides additional insights into Lupin Ltd.'s stock performance. On our website, you can access dynamic price charts that display historical price movements, technical indicators, and patterns. These charts assist investors in identifying potential entry and exit points, support and resistance levels, and trend reversals. By incorporating these insights into our premium features tools, investors can conduct a comprehensive analysis and make informed decisions about Lupin Ltd. as a long-term investment.

Lupin Ltd. News Updates

Keeping up with the latest news and developments concerning Lupin Ltd. is fundamental for long-term investors. Our website provides comprehensive and timely information sourced from reliable news channels. Through articles and news updates, investors gain insights into Lupin Ltd.'s industry trends, market position, and future outlook. This information empowers investors to make well-informed decisions and stay ahead of market dynamics affecting their long-term investment positions.

Lupin Ltd. Conference Calls

Lupin Ltd.'s conference calls offer crucial insights into the company's operations, financial performance, and growth strategies. On our platform, you can find a searchable collection of Lupin Ltd.'s conference calls, including downloadable recordings. By listening to these calls, investors gain a deep understanding of Lupin Ltd.'s management team, growth plans, and economic factors impacting the company's performance. Leveraging our premium features tools, investors can carry out comprehensive analyses and make well-informed decisions regarding their long-term investment positions in Lupin Ltd.

Lupin Ltd. Transcripts

Transcripts of Lupin Ltd.'s conference calls capture important discussions and insights. Our platform provides downloadable transcripts that include in-depth analyses of the company's financial performance, future plans, and market trends. Reviewing these transcripts offers valuable insights into Lupin Ltd.'s strategies, growth potential, and adaptability to market dynamics. By leveraging our premium features tools and conducting a comprehensive analysis, investors can make well-informed decisions about Lupin Ltd. as a long-term investment.

Lupin Ltd. Investor Presentations

Lupin Ltd.'s investor presentations offer detailed information about the company's financials, strategic initiatives, and future plans. On our platform, you can easily access these investor presentations in downloadable PDF format. These presentations provide insights beyond the numbers, delving deep into Lupin Ltd.'s growth strategy, market expansion plans, and competitive advantages. By leveraging our premium features tools and conducting thorough analyses, investors can make sound investment decisions based on Lupin Ltd.'s investor presentations.

Lupin Ltd. Promoters and Shareholders

Understanding the ownership structure of Lupin Ltd. is crucial for long-term investors evaluating the company's growth potential and stability. Our pre-built screening tools enable investors to assess promoter holdings and analyze the company's shareholder base. By understanding the distribution of ownership and the alignment of interests, investors can make well-informed decisions about their long-term investment positions in Lupin Ltd.

Lupin Ltd. ROCE

Return on Capital Employed (ROCE) is a key financial metric that indicates the efficiency and profitability of a company's capital investments. It is a crucial factor in evaluating Lupin Ltd.'s financial performance. You can conveniently access ROCE data for Lupin Ltd. in the financials table or ratio section on this page.

Lupin Ltd. EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) provides insight into Lupin Ltd.'s operating profitability. This metric is essential for assessing the company's financial health. Detailed EBITDA data for Lupin Ltd. can be found in the financials table or ratio section located on this page.

Lupin Ltd. DPS

Dividends Per Share (DPS) is a vital indicator for investors seeking information about the dividend distribution of Lupin Ltd. This page offers access to DPS data as it pertains to the company, which aids in evaluating its dividend policy and performance.

Lupin Ltd. EPS

Earnings Per Share (EPS) is a fundamental metric for analyzing Lupin Ltd.'s profitability and investment potential. This information is readily available on this page in the financials table or ratio section. EPS data allows for a comprehensive assessment of the company’s earnings and financial outlook.

Read More
X